Patents by Inventor Hubert Bayer

Hubert Bayer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HCV peptide antigens and methods for the determination of HCV
    Publication number: 20030198644
    Abstract: Novel HCV peptide antigens are described representing partial sequences of the C-100-3 and env/core with C-regions. These peptide antigens are suitable for the determination of HCV antibodies as immunogens for the production of antibodies against HCV and as vaccines for the production of vaccines against HCV.
    Type: Application
    Filed: February 21, 2003
    Publication date: October 23, 2003
    Applicant: Roche Diagnostics GmbH
    Inventors: Christoph Seidel, Gertraud Ehrlich-Weinreich, Hubert Bayer, Ursula Henrike Wienhues, Gunther Gerhard Jung, Hans Georg Ihlenfeldt
  • HCV peptide antigens and methods for the determination of HCV
    Patent number: 6592871
    Abstract: Novel HCV peptide antigens are described representing partial sequences of the C-100-3 and env/core with C-regions. These peptide antigens are suitable for the determination of HCV antibodies as immunogens for the production of antibodies against HCV and as vaccines for the production of vaccines against HCV.
    Type: Grant
    Filed: October 13, 2000
    Date of Patent: July 15, 2003
    Assignee: Roche Diagnostics GmbH
    Inventors: Christoph Seidel, Gertraud Ehrlich-Weinreich, Hubert Bayer, Ursula Henrike Wienhues, Günther Gerhard Jung, Hans Georg Ihlenfeldt
  • HCV peptide antigens and methods for the determination of HCV
    Patent number: 6183949
    Abstract: Novel HCV peptide antigens are described representing partial sequences of the C-100-3 and env/core with C-regions. These peptide antigens are suitable for the determination of HCV antibodies as immunogens for the production of antibodies against HCV and as vaccines for the production of vaccines against HCV.
    Type: Grant
    Filed: February 21, 1996
    Date of Patent: February 6, 2001
    Assignee: Roche Diagnostics GmbH
    Inventors: Christoph Seidel, Gertraud Ehrlich-Weinreich, Hubert Bayer, Ursula H Wienhues, Günther Gerhard Jung, Hans Georg Ihlenfeldt
  • HCV peptide antigens and method of determining HCV
    Patent number: 5674676
    Abstract: New HCV peptide antigens are described. These peptide antigens are suitable for the determination of HCV antibodies as immunogens for the preparation of antibodies to HCV and as immunogens for the preparation of vaccines to HCV.
    Type: Grant
    Filed: August 6, 1993
    Date of Patent: October 7, 1997
    Assignee: Boehringer Mannheim GmbH
    Inventors: Christoph Seidel, Ursula-Henrike Wienhues, Hubert Bayer, Guenther-Gerhard Jung, Hans Georg Ihlenfeldt
  • Virus solution for use in immunoassays
    Patent number: 5459033
    Abstract: The invention concerns a virus solution which contains a detergent having the general formula I and serves to stabilize the virus solution as well as its production and use in heterogeneous immunoassays for the detection of antibodies against viruses.
    Type: Grant
    Filed: April 2, 1993
    Date of Patent: October 17, 1995
    Assignee: Boehringer Mannheim GmbH
    Inventors: Heiner Vonwirth, Michael Marschall, Hubert Bayer
  • Expression of HIV1 and HIV2 polypeptides and their use
    Patent number: 5310876
    Abstract: A fusion protein with at least one antigenic and/or immunogenic determinant from the env, gag and/or pol region of HIV1 and/or HIV2 which contains the tetrapeptide sequence NH.sub.2 -Met-Tyr-Tyr-Leu as the N-terminal component as well as a process for its production and use.
    Type: Grant
    Filed: January 25, 1991
    Date of Patent: May 10, 1994
    Assignee: Boehringer Mannheim GmbH
    Inventors: Hubert Bayer, Erhard Kopetzki
  • Method for determination of HIV specific antibodies
    Patent number: 5001049
    Abstract: The invention relates to a method for determining HIV (human immunodeficiency virus) specific antibodies. A sample is incubated with a solid phase, to which streptavidin is bound in a way to make 0.1-2.5 .mu.g streptavidin per ml of reaction volume available for binding, a biotinylated polypeptide, and a labelled receptor which binds to HIV specific antibodies. The biotinylated polypeptide contains at least one of the amino acid sequences ##STR1## and is from 7 to 50 amino acids long. Following complex formation onto the solid phase, solid and liquid phase are separated, and label is measured in one of these.
    Type: Grant
    Filed: January 19, 1990
    Date of Patent: March 19, 1991
    Assignee: Boehringer Mannheim GmbH
    Inventors: Christian Klein, Hubert Bayer